VENTURA COUNTY
HEALTH CARE PLAN

**Prior Authorization DRUG Guidelines**

# **Arcalyst** (rilonacept)

Date Developed: 9/3/13 by Albert Reeves MD
Effective Date: 10/22/13
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

**(Archived 1/22/19)**

Arcalyst binds to IL-1 beta and to a lesser extent IL-1 alpha thus preventing their interactions with inflammatory cell surface receptors. This reduces the inflammatory response that results from under-production of the protein Cryopyrin due to a mutation in the NLRP-3 gene. Cryopyrin down-regulates production of IL-1.

**Pre-Authorization Criteria:** Cryopyrin-associated periodic syndromes (e.g. familial cold autoinflammatory syndrome; Muckle-Wells syndrome) in adults and children 12 years and older

**Dosing: Adult**

**Cryopyrin-associated periodic syndromes:** SubQ: Loading dose 320 mg given as 2 separate injections (160 mg each) on the same day at 2 different sites, followed by a once-weekly dose of 160 mg.

**Note:** Do not administer more frequently than once weekly.

**Dosing: Pediatric**

**Cryopyrin-associated periodic syndromes:** Children **≥12 years**: SubQ: Loading dose 4.4 mg/kg (maximum dose: 320 mg) given as 1-2 separate injections (maximum: 2 mL/injection; administer at 2 different sites if multiple injections are necessary) on the same day, followed by a once-weekly dose of 2.2 mg/kg (maximum dose: 160 mg).

**Note:** Do not administer more frequently than once weekly.

**PRECAUTIONS:**

predisposition to infection; may increase total cholesterol,HDL,LDL and trigycerides; patients should be brought up to date with all immunizations; live vaccines should not be given concurrently

VENTURA COUNTY
HEALTH CARE PLAN

**DRUG INTERACTIONS:** increased risk of infection if used with TNF-antagonists; enhanced immunosuppression and/or side effects if used with other immunosuppressants ; see product information for other drug interactions

**REFERENCES**


1. Goldback-Mansky R, Shroff SD, Wilson M, et al, "A Pilot Study to Evaluate the Safety and Efficacy of the Long-Acting Interleukin-1 Inhibitor Rilonacept (Interleukin-1 Trap) in Patients With Familial Cold Autoinflammatory Syndrome," *Arthritis Rheum*, 2008, 58(8):2432-42. [PubMed 18668591]
2. Hoffman HM, Throne ML, Amar NJ, et al, "Efficacy and Safety of Rilonacept (Interleukin-1 Trap) in Patients With Cryopyrin-Associated Periodic Syndromes: Results From Two Sequential Placebo- Controlled Studies," *Arthritis Rheum*, 2008, 58(8):2443-52. [PubMed 18668535]
3. Hoffman HM, Throne ML, Amar NJ, et al, "Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopyin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study," *Clin Ther* , 2012, 34(10):2091-103. [PubMed 23031624]
4. Miyamae T, "Cryopyrin-Associated Periodic Syndromes: Diagnosis and Management," *Pediatr Drugs*, 2012, 14(2):109-17. [PubMed 22335455]
5. Radin A, Marbury T, Osgood G, et al, "Safety and Pharmacokinetics of Subcutaneously Administered Rilonacept in Patients With Well-Controlled End-Stage Renal Disease (ESRD)," *J Clin Pharmacol*, 2010, 50(7):835-41. [PubMed 20035038]


## Revision History:

Date Approved by P&T Committee: 10/22/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 9/30/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

| Revision Date | Content Revised (Yes/No) | Contributors | Review/Revision Notes |
|---|---|---|---|
| 1/24/17 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review |
| 1/23/18 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review |
| 1/22/19 | No | Catherine Sanders, MD; Robert Sterling, MD | Archived – check ESI |